TransMedics Group, Inc. (TMDX)
US — Healthcare Sector
Automate Your Wheel Strategy on TMDX
With Tiblio's Option Bot, you can configure your own wheel strategy including TMDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TMDX
- Rev/Share 14.4782
- Book/Share 7.8973
- PB 15.7017
- Debt/Equity 1.9467
- CurrentRatio 9.0988
- ROIC 0.0654
- MktCap 4195391200.0
- FreeCF/Share -1.875
- PFCF -66.3544
- PE 85.4252
- Debt/Assets 0.619
- DivYield 0
- ROE 0.2188
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | TMDX | JP Morgan | Overweight | Neutral | $116 | $75 | Dec. 17, 2024 |
| Initiation | TMDX | Robert W. Baird | -- | Outperform | -- | $200 | Sept. 24, 2024 |
| Initiation | TMDX | Needham | -- | Buy | -- | $208 | Aug. 21, 2024 |
News
The Schall Law Firm Invites Investors With Losses In TransMedics Group, Inc. To Join A Securities Fraud Investigation
TMDX
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
About TransMedics Group, Inc. (TMDX)
- IPO Date 2019-05-02
- Website https://www.transmedics.com
- Industry Medical - Devices
- CEO Dr. Waleed H. Hassanein M.D.
- Employees 728
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.